Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific Corp (BSX), AxoGen (AXGN) and VBI Vaccines (VBIV).
Boston Scientific Corp (BSX)
In a report released yesterday, Sean Lavin from BTIG maintained a Buy rating on Boston Scientific Corp, with a price target of $45. The company’s shares closed yesterday at $34.05.
Lavin wrote:
“Sure Why BSX Buy BSX will acquire BTG plc (BTG-GB, Not Rated) for ~$4B. BTG is in of sales in the U.S. BTG focuses on interventional medicine (oncology and vascular) and also has a pharma division. We are not sure why BSX is trading down ~3%, which is about $1B. This makes little sense to us on a $4B deal. We see the interventional space as a high growth area and oncology/vascular fit within BSX salesforces. BSX has used capital well buying Asthmatx recently. Between this track record and consistently hitting targets, we thought BSX would have leeway with investors to make purchases. BTG’s business OUS, we see this deal as similar to AMS, which has been hugely successful for BSX as it has expanded sales OUS. We feel this deal should benefit BSX’s interventional business like AMMD added growth to urology.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 8.4% and a 54.9% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
Currently, the analyst consensus on Boston Scientific Corp is a Strong Buy with an average price target of $42.53, implying a 24.9% upside from current levels. In a report issued on November 15, Guggenheim also maintained a Buy rating on the stock with a $45 price target.
.
See today’s analyst top recommended stocks >>
AxoGen (AXGN)
BTIG analyst Ryan Zimmerman maintained a Hold rating on AxoGen yesterday. The company’s shares closed yesterday at $29.31.
Zimmerman wrote:
“Force Ramp Raises A Neutral AXGN hosted its annual investor day with topics focusing on an expanded TAM of existing markets, entrance into the surgical pain market and an expansion of the sales force through FY19. We feel that the expanded TAM and new opportunity in Pain were expected, but investors will have questions about the expanded sales force’s impact on growth in FY19 and beyond. With a ~44% increase in reps, combined with maintained guidance (~35% for FY19) productivity assumptions for existing reps may be lower than previously assumed if the new reps are to provide any benefit in FY19.”
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 21.0% and a 58.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
Currently, the analyst consensus on AxoGen is a Strong Buy with an average price target of $47.
VBI Vaccines (VBIV)
In a report issued on November 19, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on VBI Vaccines, with a price target of $10. The company’s shares closed yesterday at $1.64, close to its 52-week low of $1.59.
Raja observed:
“VBI Vaccines presented data from Phase 1/2a study evaluating VBI-1901 therapeutic vaccine in recurrent glioblastoma (rGBM) at the Neuro-Oncology (SNO). VBI-1901 was well tolerated in 14 patients treated so far, six patients each in the low (0.4µg) and medium dose (2.0µg) cohorts and four patients in the high-dose(10.0µg) cohort. 33% (2/6) of the patients showed immunological response in both the low and medium dose cohorts. One of the patients in the low dose cohort had PFS of 9 months. We view this as a positive development indicating a clean safety profile for VBI-1901 and promising initial immunological response. It needs to be seen if the induction of immune response leads to induction of antitumor effects, overall survival (OS) and progression-free survival (PFS) benefits.”
According to TipRanks.com, Raja is a 1-star analyst with an average return of -6.2% and a 40.6% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Corbus Pharmaceuticals, and Acer Therapeutics Inc.
VBI Vaccines has an analyst consensus of Moderate Buy, with a price target consensus of $10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
